🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being viewed as a "huge turning point" in the battle against drug-resistant strains of the bacteria, according to researchers.

An International Challenge

The sexually transmitted infection are increasing worldwide, with estimates suggesting over 82 million new cases per year. Notably increased rates are seen in the African continent and nations within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. In England, cases have reached a all-time high, while figures across Europe in 2023 were three times higher compared to those in 2014.

“The approval of new treatments for gonorrhoea is an significant and necessary step in the context of growing infection rates, the spread of superbugs and the extremely scarce available drugs presently on offer.”

Public health authorities are deeply concerned about the rise in treatment-resistant strains. The WHO has listed it as a "critical concern". Recent surveillance showed that the effectiveness of primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Treatment Options Secure Authorization

One new antibiotic, also known as Nuzolvence, was cleared by the US Food and Drug Administration in recent days for treating gonorrhoea. This infection can lead to serious health problems, including infertility. Experts believe that focused deployment of this new drug will help hinder the spread of drug resistance.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, also received approval in the same week. This drug, which is additionally indicated for urinary tract infections, was demonstrated in studies to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin stemmed from a unique collaborative effort for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to see it through.

“This milestone marks a major breakthrough in the management of highly resistant gonorrhoea, which until now has been outpacing our drug pipeline.”

Clinical Trial Outcomes and Worldwide Availability

Based on data published in a prominent scientific publication, zoliflodacin successfully treated more than 90% of uncomplicated infections. This places it at an similar efficacy with the existing first-line therapy, which involves a dual-drug approach. The study involved hundreds of patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, GARDP has the authority to register and commercialise the drug in many developing nations.

Medical professionals on the front lines have expressed hope. Access to a easy-to-administer therapy of this kind is hailed as a "game-changer" for managing the epidemic. This is considered vital to alleviate the strain of the infection for people and to stop the proliferation of untreatable gonorrhoea globally.